Valproate prescriptions for nonepilepsy disorders in reproductive‐age women

Author:

Adedinsewo Demilade A.12,Thurman David J.3,Luo Yao‐Hua3,Williamson Rebecca S.1,Odewole Oluwaseun A.4,Oakley Godfrey P.15

Affiliation:

1. Department of Epidemiology Emory University Rollins School of Public Health Atlanta Georgia

2. National Center for HIV/AIDS Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention Atlanta Georgia

3. National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia

4. Division of Nuclear Medicine and Molecular Imaging Department of Radiology Emory University Hospital Atlanta Georgia

5. Center for Spina Bifida Research Prevention and Policy, Emory University, Rollins School of Public Health Atlanta Georgia

Abstract

BACKGROUNDScientific evidence has consistently shown taking valproate during pregnancy increases risks of congenital malformations and cognitive impairment. As such, elimination of its use would be an important step in birth defects prevention. There are guidelines discouraging its use among women with epilepsy, but none exists for women without epilepsy, nor is the prevalence of valproate for nonepilepsy indications known.METHODSUsing de‐identified data from the National Hospital and Ambulatory Medical Care Surveys (1996–2007), we examined individual prescriptions for reproductive‐age adolescent girls and adult women ages 15 to 44 years in the United States, and estimated the number of antiepileptic drug and valproate prescriptions in the aggregate. We classified our study population using International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes, as women with epilepsy and women without epilepsy. The prevalence of antiepileptic drug and valproate prescriptions among women without epilepsy was estimated as prescriptions per 1000 patient visits for every 3‐year time interval and the overall study period.RESULTSWe found 83% of valproate prescriptions were issued to women without epilepsy and 74% of these were for psychiatric diagnoses. The prevalence of antiepileptic drug prescriptions among women without epilepsy tripled during the study period (10.3 [1996–1998] vs. 34.9 [2005–2007] per 1000 patient visits), whereas valproate prescriptions remained relatively stable (3.1 [1996–1998] vs. 3.7 [2005–2007] per 1000 patient visits).CONCLUSIONMost women of reproductive age who receive a valproate prescription do not have epilepsy. Valproate prescriptions did not decline, despite increasing knowledge of its teratogenicity. Reducing valproate use among women of reproductive age, especially among those who use the drug for psychiatric indications, would prevent birth defects and cognitive deficits. Birth Defects Research (Part A) 97:403–408, 2013. © 2013 Wiley Periodicals, Inc.

Publisher

Wiley

Reference41 articles.

1. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential

2. The longer term outcome of children born to mothers with epilepsy

3. Practice guideline for the treatment of patients with bipolar disorder (revision);American Psychiatric Association;Am J Psychiatry,2002

4. VALPROIC ACID AND SPINA BIFIDA

5. Valproic acid and spina bifida: a preliminary report–France;CDC;MMWR Morb Mortal Wkly Rep,1982

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3